Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Trial details
- Registry ID
- NCT07398417
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as AXS-14; Esreboxetine
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research DesignNCT07398417 | AXSM | Phase 3 | Recruiting | 2028-03Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |